| scholarly article | Q13442814 |
| P50 | author | Robin Christensen | Q57080024 |
| Bjarke B Hansen | Q58816518 | ||
| Henning Bliddal | Q80996159 | ||
| Christian Gluud | Q26265142 | ||
| P2093 | author name string | Joseph Beyene | |
| Simon Tarp | |||
| Daniel E Furst | |||
| Anna Dossing | |||
| P2860 | cites work | Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study | Q21203737 |
| Why the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard Item | Q24201550 | ||
| Why the Cochrane Risk of Bias Tool Should not Include Funding Source as a Standard Item | Q24201554 | ||
| Industry sponsorship and research outcome | Q24202591 | ||
| Biologics for rheumatoid arthritis: an overview of Cochrane reviews | Q24240731 | ||
| The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study | Q24550236 | ||
| What is meant by intention to treat analysis? Survey of published randomised controlled trials | Q24647858 | ||
| Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 | ||
| Randomized controlled trial design in rheumatoid arthritis: the past decade | Q37397646 | ||
| Modified intention to treat reporting in randomised controlled trials: systematic review | Q37765079 | ||
| CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials | Q37950739 | ||
| Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. | Q37998319 | ||
| Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review | Q38011678 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies | Q38044510 | ||
| Beyond intention to treat: what is the right question? | Q38149747 | ||
| Biologicals for rheumatoid arthritis | Q39723605 | ||
| Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors | Q40532147 | ||
| Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study | Q41111726 | ||
| Long-term outcome of treating rheumatoid arthritis: results after 20 years | Q41913707 | ||
| Missing outcomes in randomized trials: addressing the dilemma. | Q42030778 | ||
| The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis | Q42661052 | ||
| Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study | Q45228027 | ||
| Baseline observation carry forward: reasoning, properties, and practical issues | Q46395226 | ||
| Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials | Q47192223 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research | Q52036957 | ||
| Placebo-controlled studies in rheumatoid arthritis: ethical issues | Q53558680 | ||
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | Q57169471 | ||
| Rheumatoid arthritis increased the risk for myocardial infarction in women | Q57819617 | ||
| Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial | Q58234944 | ||
| Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e | Q63101754 | ||
| Missing data in trials: do we have to keep carrying the last observation forward? | Q80419496 | ||
| Missing data | Q24669904 | ||
| Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? | Q26701411 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 | ||
| Influence of trial sample size on treatment effect estimates: meta-epidemiological study | Q27687577 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q28131636 | ||
| Systematic reviews in health care: Assessing the quality of controlled clinical trials | Q29618659 | ||
| Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses | Q29619185 | ||
| Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases | Q30991316 | ||
| Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls | Q33476068 | ||
| Generalized linear mixed models for meta-analysis | Q33594559 | ||
| Strategy for intention to treat analysis in randomised trials with missing outcome data | Q33814157 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Investigating patient exclusion bias in meta-analysis. | Q34370675 | ||
| Does analysis using "last observation carried forward" introduce bias in dementia research? | Q34846882 | ||
| Intention-to-treat analysis: who is in? Who is out? | Q35027056 | ||
| Controlling the risk of spurious findings from meta-regression. | Q35782230 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis | Q36678766 | ||
| The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? | Q36937596 | ||
| P433 | issue | 9 | |
| P921 | main subject | epidemiology | Q133805 |
| bias | Q742736 | ||
| study protocol | Q111908491 | ||
| P304 | page(s) | e005297 | |
| P577 | publication date | 2014-09-26 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol | |
| P478 | volume | 4 |
| Q92665695 | Community pharmacy lifestyle intervention to increase physical activity and improve cardiovascular health of men with prostate cancer: a phase II feasibility study |
| Q91775337 | Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Do |
| Q36072546 | Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies |
| Q35770656 | Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. |
| Q89124309 | Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial |
| Q56957641 | Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q47098116 | Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. |
Search more.